Health
Free App Bets Health Data Beats the Needle
January AI's updated app merges medical records, wearable data, and CGM-free glucose prediction, free of charge—a first for digital health.
about 3 hours ago
Hospital Care Goes Remote: AI Enters the Home
Vega Health and Baptist Health partner to bring AI-driven monitoring insights to hospital-at-home care, aiming for a lasting collaboration.
20 days ago
Frozen Platelets Target a Persistent Lab Supply Gap
Retham Technologies launches cryopreserved research platelets, with Prolytix as distributor, addressing platelets' notoriously short usable life.
21 days ago
RoenRx Details 2026 Weight-Loss Program Pricing: A Comprehensive Financial Guide to Telehealth GLP-1 Treatments
RoenRx has released its detailed 2026 pricing for medically supervised weight-loss programs, including transparent costs for GLP-1 treatments (brand-name and compounded), various membership options, and all-inclusive bundled care plans, emphasizing accessibility and professional support.
about 1 month ago
New Research Institute Launched to Advance Early Biology of Breast Cancer in Young Women
The Breast Cancer in Young Women Foundation has announced the launch of the Young Women's Breast Cancer Research Institute — the first-of-its-kind scientific body dedicated to understanding why breast cancer develops early in some women, with a central focus on the biological changes that occur before a tumour ever appears.
about 1 month ago
Vaxart Directors Outline Strategy for Shareholder Value Ahead of 2026 Meeting
Vaxart's newest independent directors sent a letter to shareholders outlining their commitment to enhancing value, governance, and oral vaccine development.
about 1 month ago
Curaechoice Partners with Capitol Imaging for No-Cost Diagnostic Access
Curaechoice partners with Capitol Imaging Services to offer no-cost diagnostic imaging for its members, enhancing access to critical medical scans and reducing financial burdens.
about 1 month ago
Manassas Chiropractor Adopts Low-Force Adjusting Methods
Manassas chiropractor Dr. Gyzel Tabrizi uses low-force instrument adjusting techniques, offering a gentle yet precise alternative for spinal and joint care.
about 2 months ago
TNBC Clinical Trial Report Reveals Active Pipeline
DelveInsight's new report reveals over 350 active global clinical trials for Triple-Negative Breast Cancer, with immunotherapies and ADCs leading new treatments. North America holds the most studies.
about 2 months ago
Sensei Biotherapeutics Expands Team with Stock Grants
Sensei Biotherapeutics issued inducement stock options to three new employees under Nasdaq rules to attract key talent for its immunooncology pipeline.
about 2 months ago
Entrada Therapeutics Issues Inducement Grants to New Hires
Entrada Therapeutics announced inducement stock options for 32,500 shares to new employees, adhering to Nasdaq Listing Rule 5635(c)(4).
about 2 months ago
Revelation Biosciences Bolsters Kidney Injury Board
Revelation Biosciences expanded its Acute Kidney Injury Advisory Board with two new experts to guide the clinical development of its lead asset, REV-002.
about 2 months ago
Genentech to Unveil Obesity Data at ADA 2026
Genentech will present new data on its obesity portfolio, including GDC-9413 and GDC-7817, at the 2026 ADA Scientific Sessions. A new discovery program is also planned.
about 2 months ago
Cosmos Health Eyes $200M Revenue by 2029
Cosmos Health forecasts $200 million in revenue and $44 million Adjusted EBITDA by 2029, driven by a strategic shift to high-margin healthcare products.
2 months ago
Context Therapeutics CEO to Detail Pipeline at Jefferies Event
Context Therapeutics Inc. CEO Martin Lehr will present at the Jefferies Global Healthcare Conference on June 5, 2026, discussing the company's oncology pipeline, including ONC-392 and CTX-177.
2 months ago
Medicaid Oversight Shifts Spark Private Equity Scrutiny
States are scrutinizing private equity-backed Medicaid contractors following audits revealing performance and financial concerns. This intensifies debate over profit motives in public health services.
2 months ago
Immuneering's Atebimetinib Extends Pancreatic Cancer Survival
Immuneering reports 17.3 months median overall survival for atebimetinib in first-line metastatic pancreatic cancer, a promising step for patients.
2 months ago
Dermata Therapeutics Outlines Q1 2026 Financials and Clinical Growth
Dermata Therapeutics reported Q1 2026 financials, detailing a $7.8M net loss and progress in its DM1721 acne and rosacea clinical trials.
3 months ago